A Phase I investigator-driven clinical trial, which is ready to recruit its first participant, gives Australian patients with high-risk MDS access to two new oral drugs.
Research to further scientific knowledge of the cause and treatment of the uncommon type of blood cancer, Waldenström’s macroglobulinaemia (WM), is being co-funded by the Leukaemia Foundation.
Meet the research team developing a myeloma treatment with maximum efficacy and minimal side effects
More than 80% of children newly diagnosed with acute lymphoblastic leukaemia (ALL) are successfully treated today – an achievement deemed by Dr Michael Osborn as “one of the true success stories of modern medicine”.
Professor David Curtis has focused his research on searching for new ways to treat early T-cell precursor acute lymphoblastic leukaemia (ETP-ALL) which he describes as “a nasty type of leukaemia”.
The ability to use haploidentical donors, or half matched donors, is the most important recent development in stem cell transplantation, says world leader in transplant research, Professor David Curtis.
We spoke to Dr Sidiqi about his specialising field of amyloidosis.
Daratumumab (Darzalex®) could be the first ever therapy to be approved in Australia for AL amyloidosis.
Professor Wendy Erber and her research team in Western Australia are developing a monitoring tool they hope will identify MPN patients who will go on to develop leukaemia.
The greatest unmet need in CML is the ability to predict outcomes at the time of diagnosis according to Dr Naranie Shanmuganathan, a consultant haematologist at Royal Adelaide Hospital and SA Pathology.
